Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemia.
Allogeneic hematopoietic stem cell transplantation (alloHCT) is the single most potent treatment modality to prevent relapse in adults with acute lymphocytic leukemia, but its optimal use and timing remains a matter of intense debate and research. There is general agreement that patients with clinical features of high risk for relapse should undergo alloHCT in first complete remission. However, newer studies suggest that even patients without these risk factors may benefit. Monitoring of minimal residual disease may improve risk stratification and may complement or replace conventional risk features. Prognosis in relapsed and refractory patients is dismal, and alloHCT should be performed as soon as possible. AlloHCT also offers the only reasonable chance for cure in Philadelphia chromosome-positive acute lymphocytic leukemia; the role of imatinib is not yet clearly defined. Recent developments in unrelated-donor transplantation and reduced-intensity conditioning allow the beneficial effects of alloHCT to reach a considerably wider patient population.
Terwey
Theis H
TH
Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany. theis.terwey@charite.de
Kim
Theo D
TD
Arnold
Renate
R
D000328:Adult; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D018365:Neoplasm, Residual / Q000517:prevention & control; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000601:surgery*; D011379:Prognosis; D018570:Risk Assessment; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome